Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins

Elaine L. Shelton; Gautam K. Singh; Colin G. Nichols

doi:10.1053/j.semperi.2018.05.004

Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins

Elaine L. Shelton, Gautam K. Singh, Colin G. Nichols

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Forty years ago, non-steroidal anti-inflammatory drugs were first reported to decrease systemic prostaglandin levels and promote ductus arteriosus (DA) closure. And yet, prolonged patency of the DA (PDA) remains a significant clinical problem, complicated by imperfect therapies and wide variations in treatment strategy. There are few pharmacology-based tools available for treating PDA (indomethacin, ibuprofen, and acetaminophen), or for maintaining DA patency (PGE₁) as is needed to facilitate corrective surgery for ductus-dependent congenital heart defects. Unfortunately, all of these treatments are inefficient and are associated with concerning adverse effects. This review highlights novel potential DA drug targets that may expand our therapeutic repertoire beyond the prostaglandin pathway.

Original language	English
Pages (from-to)	221-227
Number of pages	7
Journal	Seminars in Perinatology
Volume	42
Issue number	4
DOIs	https://doi.org/10.1053/j.semperi.2018.05.004
State	Published - Jun 2018

Keywords

KATP channel
PDA
ductus arteriosus
novel drug targets

Access to Document

10.1053/j.semperi.2018.05.004

Cite this

@article{8376f850939d46708ed85fa16d656693,

title = "Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins",

abstract = "Forty years ago, non-steroidal anti-inflammatory drugs were first reported to decrease systemic prostaglandin levels and promote ductus arteriosus (DA) closure. And yet, prolonged patency of the DA (PDA) remains a significant clinical problem, complicated by imperfect therapies and wide variations in treatment strategy. There are few pharmacology-based tools available for treating PDA (indomethacin, ibuprofen, and acetaminophen), or for maintaining DA patency (PGE1) as is needed to facilitate corrective surgery for ductus-dependent congenital heart defects. Unfortunately, all of these treatments are inefficient and are associated with concerning adverse effects. This review highlights novel potential DA drug targets that may expand our therapeutic repertoire beyond the prostaglandin pathway.",

keywords = "KATP channel, PDA, ductus arteriosus, novel drug targets",

author = "Shelton, {Elaine L.} and Singh, {Gautam K.} and Nichols, {Colin G.}",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2018",

month = jun,

doi = "10.1053/j.semperi.2018.05.004",

language = "English",

volume = "42",

pages = "221--227",

journal = "Seminars in Perinatology",

issn = "0146-0005",

number = "4",

}

TY - JOUR

T1 - Novel drug targets for ductus arteriosus manipulation

T2 - Looking beyond prostaglandins

AU - Shelton, Elaine L.

AU - Singh, Gautam K.

AU - Nichols, Colin G.

PY - 2018/6

Y1 - 2018/6

N2 - Forty years ago, non-steroidal anti-inflammatory drugs were first reported to decrease systemic prostaglandin levels and promote ductus arteriosus (DA) closure. And yet, prolonged patency of the DA (PDA) remains a significant clinical problem, complicated by imperfect therapies and wide variations in treatment strategy. There are few pharmacology-based tools available for treating PDA (indomethacin, ibuprofen, and acetaminophen), or for maintaining DA patency (PGE1) as is needed to facilitate corrective surgery for ductus-dependent congenital heart defects. Unfortunately, all of these treatments are inefficient and are associated with concerning adverse effects. This review highlights novel potential DA drug targets that may expand our therapeutic repertoire beyond the prostaglandin pathway.

AB - Forty years ago, non-steroidal anti-inflammatory drugs were first reported to decrease systemic prostaglandin levels and promote ductus arteriosus (DA) closure. And yet, prolonged patency of the DA (PDA) remains a significant clinical problem, complicated by imperfect therapies and wide variations in treatment strategy. There are few pharmacology-based tools available for treating PDA (indomethacin, ibuprofen, and acetaminophen), or for maintaining DA patency (PGE1) as is needed to facilitate corrective surgery for ductus-dependent congenital heart defects. Unfortunately, all of these treatments are inefficient and are associated with concerning adverse effects. This review highlights novel potential DA drug targets that may expand our therapeutic repertoire beyond the prostaglandin pathway.

KW - KATP channel

KW - PDA

KW - ductus arteriosus

KW - novel drug targets

UR - http://www.scopus.com/inward/record.url?scp=85048587656&partnerID=8YFLogxK

U2 - 10.1053/j.semperi.2018.05.004

DO - 10.1053/j.semperi.2018.05.004

M3 - Review article

C2 - 29880312

AN - SCOPUS:85048587656

SN - 0146-0005

VL - 42

SP - 221

EP - 227

JO - Seminars in Perinatology

JF - Seminars in Perinatology

IS - 4

ER -

Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this